Prolonged anticoagulant treatment in patients with cancer: Where do we stand?

被引：2
|
作者：
Napolitano, Mariasanta [1 ]
Siragusa, Sergio [1 ]
机构：
[1] Univ Palermo, UOC Ematol Con Trapianto, Dipartimento Biomed Med Interna & Specialist, Palermo, Italy
来源：
THROMBOSIS RESEARCH | 2017年 / 158卷
关键词：
Low molecular weight heparin; Tinzaparin; Cancer associated thrombosis; Recurrences; Bleeding; MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM; VEIN THROMBOSIS; TRIAL;
D O I：
10.1016/j.thromres.2017.09.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：152 / 153
页数：2
相关论文
共 50 条
  • [1] Melatonin for gastric cancer treatment: where do we stand?
    Rafiyan, Mahdi
    Tootoonchi, Elham
    Golpour, Mahdieh
    Davoodvandi, Amirhossein
    Reiter, Russel J.
    Asemi, Reza
    Sharifi, Mehran
    Manesh, Sayyed Mehdi Rasooli
    Asemi, Zatollah
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025, 398 (02) : 1265 - 1282
  • [2] Prevention and Treatment of Cancer With Aspirin: Where Do We Stand?
    Pasche, Boris
    Wang, Minghui
    Pennison, Michael
    Jimenez, Hugo
    SEMINARS IN ONCOLOGY, 2014, 41 (03) : 397 - 401
  • [3] WHERE DO WE STAND WITH PRIMARY TREATMENT OF BREAST CANCER
    SPRATT, JS
    MISSOURI MEDICINE, 1974, 71 (12) : 676 - 678
  • [4] Ketogenic diet in the treatment of cancer - Where do we stand?
    Weber, Daniela D.
    Aminzadeh-Gohari, Sepideh
    Tulipan, Julia
    Catalano, Luca
    Feichtinger, Rene G.
    Kofler, Barbara
    MOLECULAR METABOLISM, 2020, 33 : 102 - 121
  • [5] Standard treatment in anal cancer: where do we stand and where should we go?
    Muirhead, R.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S250 - S250
  • [6] Atrial Fibrillation and Anticoagulant Treatment in End-Stage Renal Disease Patients: Where Do We Stand?
    Di Lullo, Luca
    Mariani, Marco Valerio
    Ronco, Claudio
    Bellasi, Antonio
    Lavalle, Carlo
    Chimenti, Cristina
    Paoletti, Ernesto
    Ravera, Maura
    Zanella, Monica
    CARDIORENAL MEDICINE, 2022, 12 (04) : 131 - 140
  • [7] Treatment of negative symptoms: Where do we stand, and where do we go?
    Aleman, Andre
    Lincoln, Tania M.
    Bruggeman, Richard
    Melle, Ingrid
    Arends, Johan
    Arango, Celso
    Knegtering, Henderikus
    SCHIZOPHRENIA RESEARCH, 2017, 186 : 55 - 62
  • [8] CHICKENPOX - WHERE DO WE STAND WITH TREATMENT
    WHITLEY, RJ
    JOURNAL OF PEDIATRICS, 1990, 116 (04): : 587 - 587
  • [9] Where do we stand with IPF treatment?
    Albera, C.
    Ferrero, C.
    Rindone, E.
    Zanotto, S.
    Rizza, E.
    RESPIRATORY RESEARCH, 2013, 14
  • [10] TREATMENT OF HYPERLIPIDEMIAS - WHERE DO WE STAND
    HAVEL, RJ
    AMERICAN JOURNAL OF MEDICINE, 1982, 73 (03): : 301 - 304
12345